Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 1/2020

01-02-2020 | Chlamydophila Pneumoniae | Review

Bacterial infections in acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis

Authors: Mohsen Moghoofei, Sadegh Azimzadeh Jamalkandi, Masood Moein, Jafar Salimian, Ali Ahmadi

Published in: Infection | Issue 1/2020

Login to get access

Abstract

Objective

Due to the importance of Chronic obstructive pulmonary disease (COPD) as the fourth cause of mortality worldwide and the lack of studies evaluating the prevalence of bacterial infections in disease exacerbation, this systematic review and meta-analysis was performed to determine the prevalence rate of bacterial infections in COPD patients.

Methods

PubMed, ISI Web of Science, and Scopus databases were systematically searched for population-based prevalence studies (1980–2018). MeSH terms for “Bacterial infections” and “AECOPD” were used as search keywords. The selected studies were filtered according to the inclusion and exclusion criteria. Fixed and random-effects models were used for estimation of summary effect sizes. Between-study heterogeneity, as well as publication bias, were calculated.

Results

Finally, 118 out of 31,440 studies were selected. The overall estimation of the prevalence of bacterial infection was 49.59% [95% confidence interval (CI) 0.4418–0.55]. The heterogeneity in estimating the pooled prevalence of bacterial infections was shown in the studies (Cochran Q test: 6615, P < 0.0001, I2 = 98.23%). In addition, S. pneumoniae, H. influenzae, M. catarrhalis, A. baumannii, P. aeruginosa, and S. aureus were the most prevalent reported bacteria.

Conclusions

Our results as the first meta-analysis for the issue demonstrated that bacterial infections are an important risk factor for AECOPD. Further studies must be performed for understanding the exact role of bacterial agents in AECOPD and help physicians for more applicable preventive and therapeutic measurements.
Literature
1.
Adlowitz DG, et al. Human serum and mucosal antibody responses to outer membrane protein G1b of Moraxella catarrhalis in chronic obstructive pulmonary disease. FEMS Immunol Med Microbiol. 2005;46:139–46.CrossRef
2.
Agmy G, et al. Bacterial profile, antibiotic sensitivity and resistance of lower respiratory tract infections in upper Egypt. Mediterr J Hematol Infect Dis. 2013;5:1.CrossRef
3.
Alamoudi OS. Bacterial infection and risk factors in outpatients with acute exacerbation of chronic obstructive pulmonary disease: a 2-year prospective study. Respirology. 2007;12:283–7.PubMedCrossRef
4.
Aleemullah M, et al. Bacteriological profile of patients with AECOPD-hospital based study. Int J Curr Microbiol App Sci. 2016;5:84–90.CrossRef
5.
Aydemir Y, et al. Relationship between the GOLD combined COPD assessment staging system and bacterial isolation. Int J Chronic Obstruct Pulm Dis. 2014;27:1045–1051.CrossRef
6.
Bafadhel M, et al. Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function. Int J Chronic Obstruct Pulm Dis. 2015;10:1075.CrossRef
7.
Bafadhel M, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184:662–71.PubMedCrossRef
8.
Bari M, et al. Microbes responsible for acute exacerbation of COPD. Mymensingh Med J MMJ. 2010;19:576–85.PubMed
9.
Barker BL, et al. Association between pathogens detected using quantitative polymerase chain reaction with airway inflammation in COPD at stable state and exacerbations. Chest. 2015;147:46–55.PubMedCrossRef
10.
Bathoorn E, et al. Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation. Int J Chronic Obstruct Pulm Dis. 2009;4:101.CrossRef
11.
Beasley V, et al. Lung microbiology and exacerbations in COPD. Int J Chronic Obstruct Pulm Dis. 2012;7:555.
12.
Biagini M, Rossi M. Bacterial pathogens in sputum and degree of bronchial obstruction in patients with acute exacerbation of chronic obstructive pulmonary disease. Recenti Prog Med. 2002;93:470–3.PubMed
13.
Blasi F, et al. Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J. 1993;6:19–22.PubMed
14.
Boixeda R, et al. Bacterial flora in the sputum and comorbidity in patients with acute exacerbations of COPD. Int J Chronic Obstruct Pulm Dis. 2015;10:2581.CrossRef
15.
Boixeda R, et al. Pneumonia as comorbidity in chronic obstructive pulmonary disease (COPD). Differences between acute exacerbation of COPD and pneumonia in patients with COPD. Archivos de Bronconeumología (English Edition). 2014;50:514–20.CrossRef
16.
Braeken D, et al. Bacterial aetiology and mortality in COPD patients with CAP: results from the German Competence Network, CAPNETZ. Int J Tuberc Lung Dis. 2017;21:236–43.PubMedCrossRef
17.
Cabello H, et al. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur Respir J. 1997;10:1137–44.PubMedCrossRef
18.
Cazzola M, et al. Bronchial hyperresponsiveness and bacterial respiratory infections. Clin Ther. 1991;13:157–71.PubMed
19.
Celli B, Barnes P. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2007;29:1224–38.PubMedCrossRef
20.
Chang C, et al. The changes and clinical implications of serum procalcitonin in acute exacerbations of chronic obstructive pulmonary disease. Chin J Tuberc Respir Dis. 2006;29:444–7.
21.
Chang C, et al. Value of serum procalcitonin in diagnosing bacterial lower respiratory tract infections in people with exacerbation of chronic obstructive pulmonary disease. J Peking Univ Health Sci. 2006;38:389–92.
22.
Chang C, et al. Bacterial infection, airway and systemic inflammation and clinical outcomes before and after treatment of AECOPD, a longitudinal and cross-sectional study. COPD J Chronic Obstruct Pulm Dis. 2015;12:19–30.CrossRef
23.
Char A, et al. Evidence of mycobacterial disease in COPD patients with lung volume reduction surgery; the importance of histological assessment of specimens: a cohort study. BMC Pulm Med. 2014;14:124.PubMedPubMedCentralCrossRef
24.
Chen L, et al. Composition of pathogenic bacteria of chronic obstructive pulmonary disease patients and drug resistance of gram-negative bacilli for various antibiotics. Biomed Res. 2018;29:827–9.
25.
Chin C, et al. Haemophilus influenzae from COPD patients with exacerbations induce more inflammation than colonizers. Am J Respir Crit Care Med. 2005;172:85–91.PubMedPubMedCentralCrossRef
26.
Christol TJ, et al. Antibiogram pattern of Moraxella catarrhalis isolates in acute exacerbation chronic obstructive pulmonary disease. Chemotherapy. 2011;57:94–6.PubMedCrossRef
27.
28.
D’Anna SE, et al. Bacterial–viral load and the immune response in stable and exacerbated COPD: significance and therapeutic prospects. Int J Chronic Obstruct Pulm Dis. 2016;11:445.CrossRef
29.
Dai M-Y, et al. Respiratory infectious phenotypes in acute exacerbation of COPD: an aid to length of stay and COPD Assessment Test. Int J Chronic Obstruct Pulm Dis. 2015;10:2257.
30.
Desai H, et al. Bacterial colonization increases daily symptoms in patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11:303–9.PubMedCrossRef
31.
Diederen BM, et al. The role of atypical respiratory pathogens in exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2007;30:240–4.PubMedCrossRef
32.
Domenech A, et al. Some pneumococcal serotypes are more frequently associated with relapses of acute exacerbations in COPD patients. PLoS one. 2013;8:e59027.PubMedPubMedCentralCrossRef
33.
Domenech A, et al. Infectious etiology of acute exacerbations in severe COPD patients. J Infect. 2013;67:516–23.PubMedCrossRef
34.
Duan Z, et al. Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease. Chin J Tuberc Respir Dis. 2001;24:208–11.
35.
ElFeky DS, et al. Sputum bacteriology in patients with acute exacerbation of chronic obstructive pulmonary disease. Int J Curr Microbiol App Sci. 2016;5:289–305.CrossRef
36.
Eller J, et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest. 1998;113:1542–8.PubMedCrossRef
37.
Erkan L, et al. Role of bacteria in acute exacerbations of chronic obstructive pulmonary disease. Int J Chronic Obstruct Pulm Dis. 2008;3:463.CrossRef
38.
39.
Fruchter O, et al. Airway bacterial colonization and serum C-reactive protein are associated with chronic obstructive pulmonary disease exacerbation following bronchoscopic lung volume reduction. Clin Respir J. 2016;10:239–45.PubMedCrossRef
40.
Furqan S, Paracha SAU. Frequency of Streptococcus pneumonia and Haemophilus influenza in acute exacerbation of chronic obstructive airway disease and their sensitivity to levofloxacin. Age (years). 2014;50:28.
41.
Gallego M, et al. Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors. BMC Pulm Med. 2014;14:103.PubMedPubMedCentralCrossRef
42.
Garcha DS, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax. 2012;67:1075–80.PubMedCrossRef
43.
Garcia-Nuñez M, et al. Bronchial microbiome, PA biofilm-forming capacity and exacerbation in severe COPD patients colonized by P. aeruginosa. Future Microbiol. 2017;12:379–92.PubMedCrossRef
44.
Geelen TH, et al. The host immune response contributes to Haemophilus influenzae virulence. Respir Med. 2014;108:144–52.PubMedCrossRef
45.
Groenewegen KH, Wouters EF. Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year prospective study. Respir Med. 2003;97:770–7.PubMedCrossRef
46.
Guo Z, et al. Bacteriology in acute exacerbation in patients hospitalized frequently for acute exacerbation of chronic obstructive pulmonary disease. Zhonghua yi xue za zhi. 2014;94:729–32.PubMed
47.
Hashemi SH, et al. High seroprevalence of Bordetella pertussis in patients with chronic obstructive pulmonary disease: a case-control study. Tanaffos. 2015;14:172.PubMedPubMedCentral
48.
Holm KE, et al. The impact of age on outcomes in chronic obstructive pulmonary disease differs by relationship status. J Behav Med. 2014;37:654–63.PubMedCrossRef
49.
50.
51.
Huedo-Medina TB, et al. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11:193.PubMedCrossRef
52.
Jafarinejad H et al. Worldwide prevalence of viral infection in AECOPD patients: a meta-analysis. Microb Pathogen. 2017.
53.
Jassem E, et al. Occurrence of non-spore forming anaerobic bacteria in the upper airways of patients with chronic obstructive pulmonary disease. Med Dosw Mikrobiol. 1996;48:49–54.PubMed
54.
Karnak D, et al. Chlamydia pneumoniae infection and acute exacerbation of chronic obstructive pulmonary disease (COPD). Respir Med. 2001;95:811–6.PubMedCrossRef
55.
56.
Kieszko R et al. Bacterial exacerbations of chronic obstructive pulmonary disease. The role of lung function in aetiology of exacerbation. Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina. 2003.
57.
58.
Kuwal A, et al. A Prospective study of bacteriological etiology in hospitalized acute exacerbation of COPD patients: relationship with lung function and respiratory failure. Turk Thorac J. 2018;19:19.PubMedCrossRef
59.
Lacoma A, et al. Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease. Int J Chronic Obstruct Pulm Dis. 2011;6:157.
60.
Larsen MV, et al. Bacteriology in acute exacerbation of chronic obstructive pulmonary disease in patients admitted to hospital. Scand J Infect Dis. 2009;41:26–32.PubMedCrossRef
61.
62.
Lee HY, et al. Association between Helicobacter pylori seropositivity and mild to moderate COPD: clinical implications in an Asian country with a high prevalence of H. pylori. Int J Chronic Obstruct Pulm Dis. 2016;11:2055.CrossRef
63.
Leitao Filho F et al. Comparisons between sputum molecular pathogen detection methods and microbiome sequencing in COPD Exacerbations. In: C13. The MICROBIOME IN CHRONIC AIRWAYS DISEASE, American Thoracic Society. 2018; pp. A4430-A4430.
64.
Lieberman D, et al. Infectious etiologies in acute exacerbation of COPD. Diagn Microbiol Infect Dis. 2001;40:95–102.PubMedCrossRef
65.
Lieberman D, et al. Serological evidence of Mycoplasma pneumoniae infection in acute exacerbation of COPD. Diagn Microbiol Infect Dis. 2002;44:1–6.PubMedCrossRef
66.
Lieberman D, et al. Serological evidence of Legionella species infection in acute exacerbation of COPD. Eur Respir J. 2002;19:392–7.PubMedCrossRef
67.
Lode H, et al. A prediction model for bacterial etiology in acute exacerbations of COPD. Infection. 2007;35:143.PubMedCrossRef
68.
Mantero M, et al. Role of Streptococcus pneumoniae infection in chronic obstructive pulmonary disease patients in Italy. Ther Adv Respir Dis. 2017;11:403–7.PubMedPubMedCentralCrossRef
69.
Martínez-Solano L, et al. Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin Infect Dis. 2008;47:1526–33.PubMedCrossRef
70.
Messous S, et al. Prevalence of Chlamydophila pneumoniae and Mycoplasma pneumoniae IgM and IgG antibodies in Tunisian patients presenting with exacerbation of chronic obstructive pulmonary disease. Medecine et maladies infectieuses. 2017;47:158–63.PubMedCrossRef
71.
Miller JJ. The inverse of the Freeman-Tukey double arcsine transformation. Am Stat. 1978;32:138.
72.
Miravitlles M, Anzueto A. Chronic respiratory infection in patients with chronic obstructive pulmonary disease: what is the role of antibiotics? Int J Mol Sci. 2017;18:1344.PubMedCentralCrossRef
73.
Miravitlles M, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest. 1999;116:40–6.PubMedCrossRef
74.
Mogulkoc N, et al. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Respir Crit Care Med. 1999;160(1):349–53.PubMedCrossRef
75.
76.
77.
Montero M, et al. Mortality of COPD patients infected with multi-resistant Pseudomonas aeruginosa: a case and control study. Infection. 2009;37:16–9.PubMedCrossRef
78.
Murphy TF, et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177:853–60.PubMedCrossRef
79.
Nagai K, et al. Antimicrobial susceptibilities and serotypes of Streptococcus pneumoniae in southwestern Japan and correlation of penicillin-binding protein 2b and 2x mutations in susceptibilities of penicillin G and cefotaxime. Diagn Microbiol Infect Dis. 2000;37:107–13.PubMedCrossRef
80.
Nakou A, et al. A prospective study on bacterial and atypical etiology of acute exacerbation in chronic obstructive pulmonary disease. Future Microbiol. 2014;9(11):1251–60.PubMedCrossRef
81.
Naveed A et al. Sputum culture and antibiogram in infective acute exacerbation of chronic obstructive pulmonary disease in a tertiary care hospital in India. Indian J Chest Dis Allied Sci. 2018;60:13–18.
82.
Navratilova L, et al. The Streptococcus milleri group in chronic obstructive pulmonary disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160:378–84.PubMedCrossRef
83.
Noweta K, et al. Exacerbations of chronic obstructive pulmonary disease and the role of sputum bacteriological examination. Adv Respir Med. 2006;74:396–402.
84.
Nseir S, et al. Factors predicting bacterial involvement in severe acute exacerbations of chronic obstructive pulmonary disease. Respiration. 2008;76:253–60.PubMedCrossRef
85.
Nseir S, et al. Multiple-drug–resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: prevalence, risk factors, and outcome. Crit Care Med. 2006;34:2959–66.PubMedCrossRef
86.
87.
Papaetis G, et al. Serological evidence of Mycoplasma pneumoniae infection in patients with acute exacerbation of COPD: analysis of 100 hospitalizations. Adv Med Sci. 2010;55:235–41.PubMedCrossRef
88.
Papaetis GS, et al. Serological diagnosis of Chlamydophila pneumoniae infection in Greek COPD patients by microimmunofluorescence and ELISA. Med Sci Monit. 2008;14:MT27–35.PubMed
89.
Papi A, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173:1114–21.PubMedCrossRef
90.
91.
Parameswaran GI, et al. Moraxella catarrhalis acquisition, airway inflammation and protease–antiprotease balance in chronic obstructive pulmonary disease. BMC Infect Dis. 2009;9:178.PubMedPubMedCentralCrossRef
92.
Paran H, et al. Serological, clinical and radiological findings in adults with bronchopulmonary infections caused by Chlamydia trachomatis. Isr J Med Sci. 1986;22:823–7.PubMed
93.
Patel I, et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax. 2002;57:759–64.PubMedPubMedCentralCrossRef
94.
Peng C, et al. C-reactive protein levels predict bacterial exacerbation in patients with chronic obstructive pulmonary disease. Am J Med Sci. 2013;345:190–4.PubMedCrossRef
95.
Perotin JM, et al. Detection of multiple viral and bacterial infections in acute exacerbation of chronic obstructive pulmonary disease: a pilot prospective study. J Med Virol. 2013;85:866–73.PubMedCrossRefPubMedCentral
96.
Philit F, et al. Infectious agents associated with exacerbations of chronic obstructive bronchopneumopathies and asthma attacks. Rev Mal Respir. 1992;9:191–6.PubMed
97.
Przybyłowska D, et al. Potential respiratory pathogens colonisation of the denture plaque of patients with chronic obstructive pulmonary disease. Gerodontology. 2016;33:322–7.PubMedCrossRef
98.
Ra SW, et al. Sputum bacteriology and clinical response to antibiotics in moderate exacerbation of chronic obstructive pulmonary disease. Clin Respir J. 2018;12:1424–32.PubMedCrossRef
99.
Rashid MHU, Ahmed I. Pattern of sputum bacteriology in acute exacerbations of chronic obstructive pulmonary disease. J Enam Med Coll. 2018;8:80–4.CrossRef
100.
Reissig A, et al. Microbiological diagnosis and antibiotic therapy in patients with community-acquired pneumonia and acute COPD exacerbation in daily clinical practice: comparison to current guidelines. Lung. 2013;191:239–46.PubMedCrossRef
101.
Roche N, et al. Yield of sputum microbiological examination in patients hospitalized for exacerbations of chronic obstructive pulmonary disease with purulent sputum. Respiration. 2007;74:19–25.PubMedCrossRef
102.
Rogliani P, et al. Chronic obstructive pulmonary disease and diabetes. COPD Res Pract. 2015;1:3.CrossRef
103.
Rosell A, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med. 2005;165:891–7.PubMedCrossRef
104.
Saeedi P, et al. The transient but not resident (TBNR) microbiome: a Yin Yang model for lung immune system. Inhal Toxicol. 2015;27:451–61.PubMedCrossRef
105.
Saldias P, et al. Etiology and biomarkers of systemic inflammation in mild to moderate COPD exacerbations. Rev Med Chil. 2012;140:10–8.PubMedCrossRef
106.
Saxena S et al. Bacteriological profile in acute exacerbation of chronic obstructive lung disease (AECOPD). AIMDR. 2016;2:1–6.
107.
Sethi S. Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon? Proc Am Thorac Soc. 2004;1:109–14.PubMedCrossRef
108.
Sethi S, et al. Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease. Infection. 2016;44:65–76.PubMedCrossRef
109.
Sethi S, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347:465–71.PubMedCrossRef
110.
Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev. 2001;14:336–63.PubMedPubMedCentralCrossRef
111.
Sethi S, et al. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest. 2000;118:1557–65.PubMedCrossRef
112.
Sethi S, et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176:356–61.PubMedCrossRef
113.
Sethi S, et al. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177:491–7.PubMedCrossRef
114.
Sharma P, et al. Sputum bacteriology and antibiotic sensitivity pattern in COPD exacerbation in India. Egypt J Chest Dis Tuberc. 2017;66:593–7.CrossRef
115.
Shashibhushan B, et al. Bacteriological profile and antibiotic sensitivity pattern in sputum culture of chronic obstructive pulmonary disease patients. Int J Adv Med. 2016;3:671–4.
116.
Shimizu K, et al. Pathogens in COPD exacerbations identified by comprehensive real-time PCR plus older methods. Int J Chronic Obstruct Pulm Dis. 2015;10:2009.CrossRef
117.
Simpson JL, et al. COPD is characterized by increased detection of Haemophilus influenzae, Streptococcus pneumoniae and a deficiency of Bacillus species. Respirology. 2016;21:697–704.PubMedCrossRef
118.
Singh R, et al. Inflammatory thresholds and the species-specific effects of colonising bacteria in stable chronic obstructive pulmonary disease. Respir Res. 2014;15:114.PubMedPubMedCentralCrossRef
119.
Soler N, et al. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax. 2007;62:29–35.PubMedCrossRef
120.
Soler N, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med. 1998;157:1498–505.PubMedCrossRef
121.
Sriram KB, et al. Non-typeable Haemophilus influenzae detection in the lower airways of patients with lung cancer and chronic obstructive pulmonary disease. Multidiscip Respir Med. 2018;13:11.PubMedPubMedCentralCrossRef
122.
123.
Suseela KV, et al. Bacterial profile and antibiotic susceptibility in chronic obstructive pulmonary disease patients with acute exacerbation: a cross sectional study in a tertiary care hospital. Indian J Microbiol Res. 2016;3:317–21.CrossRef
124.
Tandon MK, et al. Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest. 2010;137(4):805–11.PubMedCrossRef
125.
Tufvesson E, et al. Patients with chronic obstructive pulmonary disease and chronically colonized with Haemophilus influenzae during stable disease phase have increased airway inflammation. Int J Chronic Obstruct Pulm Dis. 2015;10:881.CrossRef
126.
Tumkaya M, et al. Relationship between airway colonization, inflammation and exacerbation frequency in COPD. Respir Med. 2007;101:729–37.PubMedCrossRef
127.
Umut S, et al. Determination of the etiological organism during acute exacerbations of COPD and efficacy of azithromycin, ampicillin-sulbactam, ciprofloxacin and cefaclor. J Chemother. 1999;11:211–4.PubMedCrossRef
128.
van der Valk P, et al. Clinical predictors of bacterial involvement in exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis. 2004;39:980–6.PubMedCrossRef
129.
Varma-Basil M, et al. Role of Mycoplasma pneumoniae infection in acute exacerbations of chronic obstructive pulmonary disease. J Med Microbiol. 2009;58:322–6.PubMedCrossRef
130.
Von Hertzen L, et al. Chlamydia pneumoniae antibodies in chronic obstructive pulmonary disease. Int J Epidemiol. 1996;25:658–64.CrossRef
131.
Wani UA, et al. Seroprevalence of Helicobacter pylori in COPD patients in Kashmir, India. COPD. 2019;1:57–8.
132.
Wedzicha JA. Role of viruses in exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004;1:115–20.PubMedCrossRef
133.
Ye F, et al. Spectrum and antimicrobial resistance of common pathogenic bacteria isolated from patients with acute exacerbation of chronic obstructive pulmonary disease in mainland of China. Chin Med J. 2013;126:2207–14.PubMed
134.
Zhao M, et al. A clinical study of bacterial infection in patients with chronic obstructive pulmonary disease. Chin J Tuberc Respir Dis. 1999;22:88–91.
135.
Zhou Y, et al. Study on the relationship between airway bacterial infections and acute exacerbations in patients with chronic obstructive pulmonary disease. Zhonghua liu xing bing xue za zhi. 2007;28:503–6.PubMed
Metadata
Title
Bacterial infections in acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis
Authors
Mohsen Moghoofei
Sadegh Azimzadeh Jamalkandi
Masood Moein
Jafar Salimian
Ali Ahmadi
Publication date
01-02-2020
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 1/2020
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-019-01350-1

Other articles of this Issue 1/2020

Infection 1/2020 Go to the issue

Case Report

Successful long-term antibiotic suppressive therapy in a case of prosthetic valve endocarditis and a case of extensive aortic and subclavian graft infection

Correction

Correction to: Real‑world experience with dalbavancin therapy in gram‑positive skin and soft tissue infection, bone and joint infection

Correction

Correction to: HBV molecular epidemiology and clinical condition of immigrants living in Italy

Case Report

Early recognition of thiamine deficiency: ocular motor deficits in a patient with nutritional deprivation due to persistent antibiotic-related nausea

Original Paper

Virulence of beta-hemolytic streptococci in infective endocarditis

Review

Native valve Staphylococcus capitis infective endocarditis: a mini review

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits